{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:00:09Z","timestamp":1789790409097,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AIRC","award":["IG2019-23069"],"award-info":[{"award-number":["IG2019-23069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and methods<\/jats:title>\n                  <jats:p>Retrospective analysis in a single reference center of 106 patients with ACC recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median follow-up was 45 months, the median recurrence-free survival (RFS) 12 months (IQR 6-23), and the median overall survival (OS) 45 months (IQR 29-75). ACC recurrences occurred as a unique lesion (group A) in 35.8%, multiple lesions in a single organ (group B) in 20.8%, and affecting multiple organs (group C) in 43.4% of patients. Baseline characteristics of patients stratified by the type of recurrence did not differ between them, except RFS, which was significantly longer in group A. Locoregional treatments were used in 100% of patients of group A, 68.2% in group B, and 26.1% in group C. After treatment of recurrence, 60.4% of patients became free of disease attaining a second RFS of 15 months (IQR 6-64). Margin status RX and R1, percent increase in Ki67, and recurrence in multiple organs were associated with an increased risk of mortality, while adjuvant mitotane treatment and longer time to first recurrence were associated with reduced risk. Recurrence in multiple organs and systemic treatment of recurrence had a negative impact on survival from the treatment of recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study shows that patients with ACC have a better prognosis when the disease recurs as a single lesion and supports the use of locoregional treatments to treat disease recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvad002","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:55:17Z","timestamp":1674111317000},"page":"118-124","source":"Crossref","is-referenced-by-count":15,"title":["The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients"],"prefix":"10.1093","volume":"188","author":[{"given":"Anna","family":"Calabrese","sequence":"first","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-6139","authenticated-orcid":false,"given":"Soraya","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Borin","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Basile","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perotti","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pia","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Berchialla","sequence":"additional","affiliation":[{"name":"Statistical Unit, Department of Clinical and Biological Sciences, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0719-105X","authenticated-orcid":false,"given":"Marco","family":"Volante","sequence":"additional","affiliation":[{"name":"Pathology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Fiori","sequence":"additional","affiliation":[{"name":"Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Porpiglia","sequence":"additional","affiliation":[{"name":"Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-063X","authenticated-orcid":false,"given":"Andrea","family":"Veltri","sequence":"additional","affiliation":[{"name":"Radiology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Reimondo","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin , 10043 Orbassano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"3","key":"2023072118405361100_lvad002-B1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023072118405361100_lvad002-B2","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2023072118405361100_lvad002-B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2023072118405361100_lvad002-B4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2023072118405361100_lvad002-B5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"11","key":"2023072118405361100_lvad002-B6","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1245\/s10434-020-09562-8","article-title":"Cumulative GRAS score as a predictor of survival after resection for adrenocortical carcinoma: analysis from the U.S. Adrenocortical Carcinoma database","volume":"28","author":"Baechle","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2023072118405361100_lvad002-B7","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: an analysis from the National Cancer Database","volume":"103","author":"Tella","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"2023072118405361100_lvad002-B8","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"23","key":"2023072118405361100_lvad002-B9","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2023072118405361100_lvad002-B10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1245\/s10434-009-0716-x","article-title":"Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane","volume":"17","author":"Grubbs","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2023072118405361100_lvad002-B11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2010.01.036","article-title":"Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer","volume":"57","author":"Porpiglia","year":"2010","journal-title":"Eur Urol"},{"issue":"S5","key":"2023072118405361100_lvad002-B12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1245\/s10434-016-5536-1","article-title":"Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit?","volume":"23","author":"Gerry","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2023072118405361100_lvad002-B13","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1530\/EJE-22-0260","article-title":"Our experience with the management of patients with non-metastatic adrenocortical carcinoma","volume":"187","author":"Terzolo","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023072118405361100_lvad002-B14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MED.0000000000000626","article-title":"Approach to patients with European Network for the Study of Adrenal Tumor stages I and II adrenocortical carcinomas","volume":"28","author":"Kastelan","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"2023072118405361100_lvad002-B15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"6","key":"2023072118405361100_lvad002-B16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-18-0923","article-title":"Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence","volume":"180","author":"Calabrese","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023072118405361100_lvad002-B17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","article-title":"Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral-center experience","volume":"107","author":"Daher","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023072118405361100_lvad002-B18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J Surg Oncol"},{"issue":"6","key":"2023072118405361100_lvad002-B19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jamcollsurg.2016.08.568","article-title":"Clinical score predicting long-term survival after repeat resection for recurrent adrenocortical carcinoma","volume":"223","author":"Tran","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"1","key":"2023072118405361100_lvad002-B20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"2023072118405361100_lvad002-B21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023072118405361100_lvad002-B22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2023072118405361100_lvad002-B23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"issue":"11","key":"2023072118405361100_lvad002-B24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14737140.2018.1510325","article-title":"Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options","volume":"18","author":"Puglisi","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"2023072118405361100_lvad002-B25","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cancers12092615","article-title":"Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer","volume":"12","author":"Basile","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2023072118405361100_lvad002-B26","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o, p\u2032DDD, o, p\u2032DDA, and o, p\u2032DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023072118405361100_lvad002-B27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023072118405361100_lvad002-B28","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/jcm8111850","article-title":"Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment","volume":"8","author":"Puglisi","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"2023072118405361100_lvad002-B29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/jpm11040269","article-title":"What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question","volume":"11","author":"Basile","year":"2021","journal-title":"J Pers Med"},{"issue":"4","key":"2023072118405361100_lvad002-B30","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023072118405361100_lvad002-B31","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0039-6060(97)90229-4","article-title":"Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma","volume":"122","author":"Bellantone","year":"1997","journal-title":"Surgery"},{"issue":"1","key":"2023072118405361100_lvad002-B32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1245\/s10434-015-4810-y","article-title":"Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence","volume":"23","author":"Amini","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2023072118405361100_lvad002-B33","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1007\/s00330-020-07019-w","article-title":"Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation","volume":"30","author":"Veltri","year":"2020","journal-title":"Eur Radiol"},{"issue":"11","key":"2023072118405361100_lvad002-B34","doi-asserted-by":"crossref","first-page":"e4698","DOI":"10.1210\/clinem\/dgab449","article-title":"Combination of mitotane and locoregional treatments in low-volume metastatic adrenocortical carcinoma","volume":"106","author":"Boileve","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023072118405361100_lvad002-B35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2023072118405361100_lvad002-B36","doi-asserted-by":"crossref","first-page":"9362108","DOI":"10.1155\/2018\/9362108","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","journal-title":"Biomed Res Int"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad002\/48763870\/lvad002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/1\/118\/50927958\/lvad002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/1\/118\/50927958\/lvad002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T18:41:20Z","timestamp":1689964880000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/188\/1\/118\/6991974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad002","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]}}}